-
CELL: Single-cell sequencing reveals how drug therapy induced the evolution of lung cancer in humans.
Time of Update: 2020-09-23
single-cell map of more than 20,000 cancer and tumor micro-environments (TME) exposes a rich and dynamic tumor ecosystem, and scRNA-seq of cancer cells reveals clinically d'ethonically available targeted cancer genes.
-
Cell Death Dis:lncRNA LRRC75A-AS1 promotes the development of triple negative breast cancer.
Time of Update: 2020-09-23
Reescue rescue experiment also showed that LRRC75A-AS1 in TNBC was able to promote cell proliferation, invasion, and EMT processes by targeting miR-380-3p/BAALC pathps.
-
Cell Death Dis:lncRNA PCAT6 promotes the occurrence and angiogenesty of triple negative breast cancer.
Time of Update: 2020-09-23
overall, the expression of M2 macrophage-induced lncRNA PCAT6 can regulate the expression level of VEGFR2 through ceRNA form and de-ubibination, thus promoting the occurrence of triple-negative breast cancer.
-
Cell Death Dis: Ubiganized modified negative regulator ERR beta promotes the development of breast cancer.
Time of Update: 2020-09-23
same internal and external source experiments have shown that MLN4924, a NEDDylation-specific small molecule inhibitor, restores the expression level of ERR beta and ultimately weakens the proliferation and migration of breast cancer cells.
-
Cell Death Dis:FXR plays a carcinogenic role in colorectal tumors by antagoning the Wnt/beta-catenin signal.
Time of Update: 2020-09-23
study, we looked at the correlation between FXR and Wnt/beta-catenin signal transductivity paths during the development of colorectal cancer.
-
Cell Death Dis:BRD9 activates the TUFT1/AKT path pathfectal path to promote the growth and metastasis of hepatocellular carcinoma.
Time of Update: 2020-09-23
all, the study showed that BRD9 can promote the growth and metastasis of liver cancer cells by activating the TUFT1/AKT pathrapy, which may be a potential biomarker and therapeutic target for HCC.
-
Molecular Cell: DNA damage promotes the degradation of TMPRSS2-ERG cancer proteins and inhibits prostate cancer progression.
Time of Update: 2020-09-23
the elimination of the cancer-related gene PTEN or infergic GSK3 beta eliminates the degradation of TMPRSS2-ERG induced by DNA damage.
-
Li Wei Reviews . . . TCR-T cell therapy, three major obstacles to be broken.
Time of Update: 2020-09-23
car proteins to identify tumor targets on the surface of cells, but terabyte tCR only allows cell therapy to kill cells that have cancer stress signals.
-
Cancer Cell: More powerful! Liao Xuebin/Wei Li collaboration reveals that HPK1 can be a target for T-cell immunotherapy.
Time of Update: 2020-09-23
further demonstrated that genetic depletion, pharmacological inhibition, or protein hydrolysis of HPK1 mediated by proTAC can improve the effectiveness of CAR-T cell-based immunotherapy in various preclinical mouse models of blood and solid tumors.
-
NEJM:Tabrecta treats METex14-jumping non-small cell lung cancer with positive results from key studies.
Time of Update: 2020-09-23
/missing exon 14 jumps. Jeff Legos, head of oncology development at Novart, said: "The data published today not only confirm our previous positive results in the use of Tabrecta in non-small cell lung cancer, but also highlight the value of early
-
Cell Death Dis: EphA2 Y772 phosphate is essential for the development of nasopharyngeal cancer.
Time of Update: 2020-09-23
in summary, the study showed that EphA2 protein 772th tyrosine phosphate is essential for the growth of EphA2-dependent nasopharyngeal cancer cells, a process achieved by activating the Shp2/Erk-1/2 signaling path.
-
Nat Commun: HIF-1 alpha and HIF-2 alpha play the opposite regulatory role in renal transparent cell carcinoma.
Time of Update: 2020-09-23
Although studies on ccRCC have shown that HIF-1 alpha is an inhibitor of invasive tumor behavior and HIF-2 alpha has a promoting effect, it is not clear what role the two play in tumor development.
-
Clin Cancer Res: PD1 blocking enhances the effectiveness of IAM1-targeted CAR T cells in the treatment of advanced thyroid cancer.
Time of Update: 2020-09-23
addition, the tumor targeting effect and T-cell dynamics of ICM1 targeted CAR T cells and anti-PD1 antibody mono-use and joint therapy were studied in the ATC heterogeneous graft model.
-
NEJM:Tepotinib treated met exon 14 jump mutation non-small cell lung cancer phase II clinical effect was significant.
Time of Update: 2020-09-23
study, tepotinib treatment response rate was about 50% for patients with advanced non-small cell lung cancer with met exon 14 jump mutation, and the most common adverse events above level 3 were exostular edema.
-
Blood: Immune escape from PD-1 is a defining feature of large B-cell lymphoma rich in T-cells/tissue cells.
Time of Update: 2020-09-23
, the unbiased aggregation of spatially differentiated immune characteristics distinguishes TCRLBCL from the associated B-cell lymphoma subtypes, including classic Hodgkin's lymphoma and DLBCL-NOS.
-
Nature: Cancer cells evade the immune system by fighting for methionine, Professor Zhai Weiping
Time of Update: 2020-09-23
study illustrates the link between these three questions, suggesting that targeting tumor cell methionine transport proteins can promote immune responses in different tumors.
-
Nature: Finally know why cancer cells are so "big", it turns out that they are more "grabbing food"
Time of Update: 2020-09-23
further analysis, the researchers determined that the high expression of SLC43A2 in tumors was associated with a decrease in T-cell immune response in cancer patients.
-
Cell Death Differ: TRIM22 activates the NF-B signal by accelerating I-B alpha degradation.
Time of Update: 2020-09-23
trim protein family, a sub-family of RENING-type E3 ubiquitin connective enzymes, can act as a key regulatory factor in the development of a variety of cancers, including GBM, by regulating the transcriptional activity of NF-B.
-
Genome Med: Wu Dasun Chengchao and others reveal the important role of LINC00301 in the progress of non-small cell lung cancer and tumor immunity.
Time of Update: 2020-09-23
that linC00301's 83-123 nucleotide bits can be directly combined with the flavoring enhancer 2 (EZH2) 612-727 amino acid bit specificity, LINC00 301 will form a complex with EZH2 and collect the latter rich in ELL protein-related factor 2 (EAF2) promoting
-
PD-L1 monoantial Imfinzi has been approved in Japan to treat a wide range of small cell lung cancer.
Time of Update: 2020-09-23
AstraZeneca's PD-L1 monoantigen-imfinzi (durvalumab) has been approved in Japan to treat patients with extensive stage small cell lung cancer (ES-SCLC) in combination with espressoside and a platinum chemotherapy drug (carbapene or cisplatin).
